Drugs / Trastuzumab Rezetecan
Trials 100 · started per year
today
1
2
7
14
13
35
28
2021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07275242 | Dec 2025 → Jun 2027 expected | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06710990 | Feb → Oct 2025 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04513223 | Mar 2021 → Mar 2025 | colorectal cancer, gastric cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04446260 | Sep 2020 → Jun 2025 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/214 trials | ||||||
| Phase 1/2 | NCT07140393 | Oct 2025 → Oct 2027 expected | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07177950 | Sep 2025 → Sep 2028 expected | breast cancer, metastatic malignant neoplasm in the brain, neoplastic meningitis | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06990516 | Jun 2025 → Jun 2030 expected | ovarian cancer | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06859775 | Apr 2025 → Oct 2026 expected | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06840002 | Mar 2025 → May 2026 overdue | ovarian carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06788197 | Mar 2025 → Mar 2028 expected | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06718933 | Jan 2025 → Aug 2026 overdue | breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06222879 | Feb 2024 → Oct 2026 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06015048 | Aug 2023 → Nov 2026 expected | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05845138 | Jul 2023 → Dec 2024 | breast cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05792410 | Apr 2023 → Feb 2024 | Her2-receptor negative breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05824325 | Mar 2023 → Apr 2025 overdue | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05482568 | Sep 2022 → Dec 2026 expected | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04818333 | Apr 2021 → Jun 2025 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 264 trials | ||||||
| Phase 2 | NCT07699952 | Jul 2026 → Mar 2029 expected | non-small cell lung carcinoma | Yongsheng Wang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07630077 | Jul 2026 → Jul 2027 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07631884 | Jun 2026 → Dec 2028 expected | biliary tract neoplasm, colorectal neoplasm, endometrium neoplasm, gastric neoplasm +5 | Haihua Yuan | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07560475 | Jun 2026 → Dec 2028 expected | HER2 positive breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07639983 | Jun 2026 → Jun 2028 expected | infiltrating bladder urothelial carcinoma | Sheng Tai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07624201 | Jun 2026 → Jun 2028 expected | urinary bladder carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07630103 | Jun 2026 → Jun 2031 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07618923 | Jun 2026 → Jun 2028 expected | hormone receptor-positive breast cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527806 | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07528898 | May 2026 → Jul 2027 expected | breast cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07489703 | Apr 2026 → Dec 2027 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07670273 | Apr 2026 → Apr 2027 expected | biliary tract cancer | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07497386 | Apr 2026 → Jun 2028 expected | breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07704177 | Apr 2026 → Apr 2027 expected | biliary tract neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07417241 | Mar 2026 → Jan 2029 expected | HER2 positive breast carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07466303 | Mar 2026 → Feb 2028 expected | female breast carcinoma, progesterone-receptor negative breast cancer | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07647263 | Mar 2026 → Jun 2029 expected | HER2 positive breast carcinoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT07466927 | Mar 2026 → Jan 2028 expected | Her2-receptor negative breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07203729 | Mar 2026 → Jun 2030 expected | breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07416253 | Mar 2026 → Mar 2027 expected | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07317778 | Feb 2026 → Oct 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07383818 | Feb 2026 → Feb 2028 expected | hormone receptor-positive breast cancer | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07340398 | Dec 2025 → Dec 2028 expected | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07307287 | Dec 2025 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07309770 | Dec 2025 → Sep 2027 expected | bladder urachal carcinoma | Sheng Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT07305246 | Dec 2025 → Mar 2027 expected | breast cancer | First Hospital of China Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07281209 | Dec 2025 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07241793 | Nov 2025 → Jul 2028 expected | urothelial carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07129018 | Nov 2025 → Nov 2027 expected | biliary tract cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07051486 | Oct 2025 → Feb 2026 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07129187 | Oct 2025 → Oct 2026 expected | HER2 positive breast carcinoma, female breast carcinoma | Chuan Wang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07102901 | Sep 2025 → Dec 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06973525 | Sep 2025 → May 2027 expected | HER2 positive breast carcinoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07132242 | Aug 2025 → Aug 2028 expected | HER2 positive breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07110571 | Aug 2025 → Aug 2026 overdue | gastric cancer, gastroesophageal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07037199 | Aug 2025 → Jun 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07047755 | Jul 2025 → Jul 2026 overdue | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06975462 | Jun 2025 → Jun 2027 expected | breast cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06975475 | Jun 2025 → Jun 2027 expected | breast cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06881017 | May 2025 → Aug 2029 expected | gastric cancer, gastroesophageal junction adenocarcinoma | China Medical University, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06927180 | Apr 2025 → May 2029 expected | female breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06778031 | Feb 2025 → Jun 2028 expected | carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06666166 | Dec 2024 → Jul 2028 expected | colorectal cancer, gastric carcinoma, gastroesophageal junction adenocarcinoma | Yunpeng Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06649331 | Oct 2024 → Sep 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06547736 | Oct 2024 → Mar 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06592625 | Sep 2024 → Feb 2026 overdue | breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06340230 | Aug 2024 → Feb 2026 overdue | hormone receptor-positive breast cancer | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06433609 | Aug 2024 → Mar 2027 expected | breast cancer | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06413745 | Jun 2024 → Dec 2026 expected | carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06411457 | May 2024 → May 2025 | breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT06361979 | May 2024 → May 2025 | female breast carcinoma | Huihua Xiong | Unknown | No outcome recorded |
| Phase 2 | NCT05924256 | Jul 2023 → Dec 2026 expected | salivary gland carcinoma | Fudan University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05896020 | Jul 2023 → Jun 2026 | female reproductive organ cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05911958 | Jul 2023 → Dec 2024 overdue | breast carcinoma by gene expression profile | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05769010 | Mar 2023 → Dec 2028 expected | breast cancer | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05749588 | Mar 2023 → Dec 2027 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05635487 | Mar 2023 → Feb 2025 overdue | HER2 positive breast carcinoma | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05671822 | Mar 2023 → Dec 2027 expected | gastroesophageal adenocarcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05076682 | Jun 2022 → Dec 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05349409 | Jun 2022 → Nov 2024 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05353361 | May 2022 → Dec 2025 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07676162 | Jul 2026 → Sep 2029 expected | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07679360 | Jul 2026 → Dec 2030 expected | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07528716 | May 2026 → Dec 2027 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07196774 | Oct 2025 → Dec 2027 expected | breast carcinoma by gene expression profile | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07111832 | Aug 2025 → Mar 2028 expected | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07118527 | Aug 2025 → Oct 2030 expected | gastroesophageal adenocarcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06990503 | Jun 2025 → Jun 2030 expected | ovarian cancer | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06828354 | Mar 2025 → May 2027 expected | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06430437 | Jul 2024 → Feb 2026 overdue | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06199973 | Mar 2024 → Apr 2026 overdue | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06123494 | Jan 2024 → Jun 2027 expected | gastroesophageal adenocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06126640 | Nov 2023 → Apr 2030 expected | HER2 positive breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06057610 | Oct 2023 → Oct 2027 expected | HER2 positive breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05814354 | Jun 2023 → Jan 2025 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05424835 | Aug 2022 → Dec 2026 expected | HER2 positive breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07600164 | Jul 2026 → Dec 2031 expected | HER2 positive breast carcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07589699 | May 2026 → Dec 2028 expected | HER2 positive breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07377916 | Feb 2026 → Jun 2029 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07355764 Comparator | Dec 2025 → Jan 2028 expected | colorectal cancer | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07100600 Background | Aug 2025 → Jul 2030 expected | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07047443 Background | Aug 2025 → Dec 2027 expected | breast cancer | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07669610 Comparator | Oct 2026 → Sep 2028 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07382687 Comparator | Feb 2026 → Dec 2028 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 108 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trastuzumab rezetecan | “A Randomized, Open-Label, Phase II Study Comparing the Efficacy and Safety of Trastuzumab-rezetecan and Trastuzumab Deruxtecan (T-DXd) in Neoadjuvant Treatment of Patients With...” NCT07416253 ↗24“Trastuzumab rezetecan (also known as SHR-A1811) is a novel antibody-drug conjugate consisting of a humanised HER2-directed monoclonal antibody, cleavable tetrapeptide-based...” PMID 40020696 ↗ Feb 2025 “Trastuzumab Rezetecan (SHR-A1811) is administered at a dose of 4.8 mg/kg every 21 days (q3w), constituting one treatment cycle.” NCT07309770 ↗ “EGFR-TKI combined with Trastuzumab Rezetecan(HER2 ADC)” NCT07699952 ↗ |
| Known as | ruikang-trastuzumab | “SHR-A1811 (ruikang-trastuzumab), a domestically developed ADC by Hengrui Pharmaceutical” NCT07307287 ↗ |
| Known as | SHR - A1811 | “Trastuzumab Rezetecan (SHR-A1811) Versus Chemotherapy of Physician's Choice in Patients With HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis：A...” NCT07203729 ↗88“Injection SHR - A1811 (hereinafter referred to as SHR - A1811) is an antibody - drug conjugate (ADC) targeting the HER2 protein” NCT06990503 ↗ “SHRA1811(HER-targeted ADC) 4.8 mg/kg, administered via intravenous infusion on Day 1 of each 3-week cycle.” NCT07669610 ↗ “Patients with advanced breast cancer expressing HER2 received SHR-A1811 + carboplatin treatment.” NCT07047443 ↗ “SHR-A1811 (ruikang-trastuzumab), a domestically developed ADC by Hengrui Pharmaceutical” NCT07307287 ↗ “SHR-A1811: 4.8mg/kg given into the vein (IV; intravenously) every 21 days” NCT07527806 ↗ “Trastuzumab Rezetecan (SHR-A1811) combined with ivonescimab (AK112)” NCT07630077 ↗ “Trastuzumab Rezetecan (SHR-A1811)” NCT07647263 ↗ “Drug: SHR- A1811” NCT05896020 ↗ |
| Known as | Trastuzumab Restuzumab | “SHR-A1811 (Trastuzumab Restuzumab , an antibody-drug conjugate)” NCT07466303 ↗ |
| Action | Inhibit | “an anti-HER2 antibody-drug conjugate (ADC)” NCT05749588 ↗ |
| Modality | Monoclonal antibody | “an anti-HER2 antibody-drug conjugate (ADC)” NCT05582499 ↗ |
| Route | Intravenous | “SHR-A1811 was administered intravenously at doses ranging from 1.0 to 8.0 mg/kg once every 3 weeks.” PMID 38900984 ↗ Jun 2024 |
| Target | ERBB2 | “antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2)” PMID 41779980 ↗ Mar 2026 |